Evaluation of Contact Lens Saline Solutions With Scleral GP Contact Lens Wearers Experiencing Fogging

NCT ID: NCT03525704

Last Updated: 2021-01-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-04-09

Study Completion Date

2018-12-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluation of saline solutions used with scleral rigid gas permeable contact lens wearers experiencing debris in the post lens tear reservoir

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

One-month, approximately 36 subjects enrolled (\~12/site), randomized, double-masked crossover trial.

Existing scleral rigid gas permeable (RGP) contact lens wearing subjects are randomly assigned (block) to different arms of the trial and receive different saline solutions for use sequentially for 2-week periods. The subjects will continue to wear their existing scleral GP lenses if lens fit is acceptable following an initial evaluation. Subjects will agree to complete a survey administered daily (via email) that will address contact lens wear time and subjective symptoms.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Contact Lens Complication Debris in Post Lens Tear Reservoir

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

One-month, approximately 36 subjects enrolled (\~12/site), randomized, double-masked crossover trial.
Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators
Randomized, Double-Masked

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Saline Solution Enriched

Saline Solution enriched with electrolytes and PH balanced to mimic normal tears

Group Type EXPERIMENTAL

Saline Solution Enriched

Intervention Type DEVICE

Sterile single dose, Preservative Free, PH Balanced, Enriched with IONs rinsing and Insertion Solution

Saline Rinse Solution

Saline Solution .9% NaCL

Group Type ACTIVE_COMPARATOR

Saline Rinse Solution

Intervention Type DEVICE

sterile unit dose non-preserved, 0.9% NaCl (normal saline) solution i

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Saline Solution Enriched

Sterile single dose, Preservative Free, PH Balanced, Enriched with IONs rinsing and Insertion Solution

Intervention Type DEVICE

Saline Rinse Solution

sterile unit dose non-preserved, 0.9% NaCl (normal saline) solution i

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

NutriFill GatorFill LacriPure ScleralFil

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Daily wear large diameter (scleral) rigid gas permeable contact lens wearers in design with acceptable fit
* 18 years old or above.
* Agree to and sign Informed Consent.
* Correctable to at least 20/40 distance visual acuity in each eye.
* Presence of debris or "fogging" in post lens tear film reservoir (PLTR).

Exclusion Criteria

* Extended wear contact lens wearers
* Require concurrent ocular medication.
* Grade 2 or more slit lamp findings (does not include fogging assessment).
* Eye injury or surgery within twelve weeks immediately prior to enrolment for this trial.
* Currently enrolled in an ophthalmic clinical trial.
* Pregnant or lactating
* Evidence of active ophthalmic disease or abnormality including glaucoma, chorioretinitis, central retinal artery or vein occlusion, intraocular or ocular infection.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Andre Vision and Device Research

UNKNOWN

Sponsor Role collaborator

The Contact Lens Center at Optique

UNKNOWN

Sponsor Role collaborator

Premiere Vision Group

UNKNOWN

Sponsor Role collaborator

Havasu Eye Center

UNKNOWN

Sponsor Role collaborator

Contamac Ltd

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bret Andre, MS, ABOe

Role: STUDY_DIRECTOR

AVD Research

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Andre Vision and Device Research

West Linn, Oregon, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AVDR 2018-01 v1.2

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.